Blood Pressure Reduction and Changes in Antihypertensive Medication Use Among Patients With Hypertension Who Initiated Sodium‐Glucose Cotransporter‐2 Inhibitors
The Journal of Clinical Hypertension · 2024
DOI: 10.1111/jch.14915 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, 2024. Verfasst von Jaejin An und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Hypertension, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) have demonstrated a blood pressure (BP) reduction benefit despite other indications for use. We evaluated BP changes and antihypertensive medication use pre‐ and post‐SGLT2i initiation among 12 960 patients with treated hypertension and among subgroups with apparent treatment‐resistant hypertension (aTRH) and/or proteinuria. Post‐SGLT2i initiation, the mean (SD) systolic blood pressure (SBP) was reduced from 133.9 (16.4) to 128.6 (15.5) mmHg and the mean diastolic blood pressure (DBP) was reduced from 70.8 (11.8) to 68.3 (11.3) mmHg among all patients. The mean SBP/DBP reduction was 5.3/2.5, 6.2/2.8, and 6.1/2.9 mmHg among all patients, patients with aTRH, and patients with proteinuria, respectively. Achieved BP < 130/80 mmHg increased by 12.5%, 16.9%, and 11.1% for all patients, patients with aTRH, and patients with proteinuria, respectively. Discontinuation of ≥ 1 antihypertensive medication within 12 months of SGLT2i initiation occurred in 33.4% overall, 47.6% of patients with aTRH, and 38.7% of patients with proteinuria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
- Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, USA.
- Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California, USA.
- Kaiser Permanente Panorama City Medical Center, Panorama City, California, USA.
ORCID-Profile: Jaejin An
Zitieren
APA
An, J., Sim, J. J., Zhou, M. M., Zhou, H., Choi, S. K., Brettler, J. W., Ong-Su, A. L., & Reynolds, K. (2024). Blood Pressure Reduction and Changes in Antihypertensive Medication Use Among Patients With Hypertension Who Initiated Sodium‐Glucose Cotransporter‐2 Inhibitors. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14915
Vancouver
An J, Sim JJ, Zhou MM, Zhou H, Choi SK, Brettler JW, et al. Blood Pressure Reduction and Changes in Antihypertensive Medication Use Among Patients With Hypertension Who Initiated Sodium‐Glucose Cotransporter‐2 Inhibitors. The Journal of Clinical Hypertension. 2024. doi:10.1111/jch.14915
BibTeX
@article{An2024,
author = {An, Jaejin and Sim, John J and Zhou, Matt M and Zhou, Hui and Choi, Soon Kyu and Brettler, Jeffrey W and Ong-Su, Angeline L and Reynolds, Kristi},
title = {Blood Pressure Reduction and Changes in Antihypertensive Medication Use Among Patients With Hypertension Who Initiated Sodium‐Glucose Cotransporter‐2 Inhibitors},
journal = {The Journal of Clinical Hypertension},
year = {2024},
doi = {10.1111/jch.14915}
}
EUVIMED